X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration

X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration


Chem to receive upfront payment and potential research, development and regulatory milestones and licensing fees, plus additional royalties on future sales )--X-Chem, Inc. , a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a collaboration with Vertex Pharmaceuticals Incorporated . Under the terms of the agreement, X-Chem will apply its proprietary DEXTM libraries, which contain more than 120 billion small molecules, toward the discovery of new drug leads against targets involved in multiple specialty diseases.



from Biotech News